Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03505801 · ClinicalTrials.gov registry record
Confirm Rx Insertable Cardiac Monitor SMART Registry
A clinical trial of Atrial Fibrillation and Symptoms and Signs, sponsored by Abbott Medical Devices.
- Active
- Registry status
- 1,826
- Enrollment target
- 20
- Study locations
NCT03505801: Active study of Atrial Fibrillation and Symptoms and Signs, sponsored by Abbott Medical Devices.
NCT03505801 is a study of Atrial Fibrillation and Symptoms and Signs that is active but no longer recruiting, run by Abbott Medical Devices. The registered enrollment target is 1,826 participants, below the 2,988-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03505801, a study of Atrial Fibrillation and Symptoms and Signs, is active but no longer recruiting, sponsored by Abbott Medical Devices.
- ACTIVE NOT RECRUITING
- Registry status
- 1,826 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the Confirm Rx SMART Registry is to collect real world data to assess the safety and performance of the Confirm Rx Insertable Cardiac Monitor (ICM) and system over a 12 month period. A sub-set of subjects enrolled in the Confirm Rx SMART Registry will meet the Post Market Clinical Follow-Up (PMCF) requirement for CE mark.
Conditions Studied
Interventions
- DEVICE Confirm Rx ICM insertion procedure
Study Locations (20)
Other
- Hôpital Central de l'Armée - Algiers
- Instituto Argentino de Diagnostico y Tratamiento - Buenos Aires
- Clinica Provincial - Merlo
- Kepler Universitätsklinikum GmbH - Linz
- Krankenhaus der Stadt St. Pölten - Sankt Pölten
Florida
- Bay Area Cardiology Associates PA - Brandon
- Bayfront Medical Center - St. Petersburg
Idaho
- St. Luke's Regional Medical Center - Boise
- Kootenai Heart Clinics - Coeur d'Alene
Maryland
- MedStar Health Research Institute - Hyattsville
- Adventist HealthCare White Oak Medical Center - Silver Spring
Pennsylvania
- Pinnacle Health System - Harrisburg
- Cardiology Consultants of Philadelphia - Yardley
Tennessee
- Erlanger Medical Center - Chattanooga
- St. Thomas Hospital - Nashville
Arkansas
- Arrhythmia Research Group - Jonesboro
Iowa
- Iowa Heart Center - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,826 participants |
| Start Date | 2018-04-24 |
| Est. Completion | 2026-03-31 |
What the registry record for NCT03505801 still lists
NCT03505801 is an observational study that tracks outcomes without assigning an intervention. Its 1,826 participants enrollment target places it among the larger protocols in the corpus, below the 2,988-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (39% lower).
The record links to 3 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Confirm Rx ICM insertion procedure is the first listed.
NCT03505801 names 20 study sites across 11 states, led by Other, Florida, Idaho.
Frequently Asked Questions
What is clinical trial NCT03505801 about?
NCT03505801 is a clinical study titled "Confirm Rx Insertable Cardiac Monitor SMART Registry". The purpose of the Confirm Rx SMART Registry is to collect real world data to assess the safety and performance of the Confirm Rx Insertable Cardiac Monitor (ICM) and system over a 12 month period. A sub-set of subjects enrolled in the Confirm Rx SMART Registry will meet the Post Market Clinical Fol...
What is the current status of trial NCT03505801?
This trial is currently active not recruiting. The enrollment target is 1,826 participants. The study started on 2018-04-24. Estimated completion is 2026-03-31.
What conditions does trial NCT03505801 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Symptoms and Signs, Cardiac Arrhythmias.
What interventions are being tested in trial NCT03505801?
The interventions under investigation include: Confirm Rx ICM insertion procedure (DEVICE).
Who is sponsoring clinical trial NCT03505801?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03505801 being conducted?
This trial has 20 study locations across Arkansas, Florida, Idaho, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03505801's enrollment target sits among peer trials
1,826 29th of 202 higher than 174 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI